Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been demonstrated to show efficacy in non‐small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations [1, 2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.